Berta Renedo Miró

Berta Renedo Miró

Auto-generated profile, based on publicly available information

Berta Renedo Miró

Pharmacy Department, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2026 in BJUI Compass
Verified
Journal Article
Open access
JMJuan Morote
Juan Morote
BMBerta Miró
Berta Miró
LRLucas Regis
Lucas Regis
FCFrançois Cousin
François Cousin
PDPatrick Duflot
Patrick Duflot
OMOlga Méndez
Olga Méndez

12 August 2026 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
MTMaria Álvarez de Toledo
Maria Álvarez de Toledo
MZMaria Blanca Guembe Zabaleta
Maria Blanca Guembe Zabaleta
LBLaura Barenblit-Mas
Laura Barenblit-Mas
MLMaria Larrosa-Garcia
Maria Larrosa-Garcia
AFAurora Fernandez-Polo
Aurora Fernandez-Polo
PSPere Soler-Palacín
Pere Soler-Palacín
Background: Posaconazole suspension is widely used for the prophylaxis of breakthrough invasive fungal infections in high-risk children. Due to its low bioavailability and high pharmacokinetic variability, therapeutic drug monitoring (TDM) is recommended. Objectives: To describe prophylactic posaconazole suspension TDM in children, evaluate its effectiveness and investigate factors influencing its pharmacokinetics. Methods: Retrospective observational study from 2017–2023, including consecutive patients <18 years receiving prophylaxis with posaconazole suspension for ≥1 week and with ≥1 posaconazole serum concentration (trough concentration [C trough ]). Results: Seventy-one patients were included (median age 4.8 [interquartile range, IQR 2.4–8.9] years). The most frequent underlying condition was inborn errors of immunity (23, 32.4%); 55 patients (77.5%) had undergone hematopoietic stem-cell transplantation. Out of 373 C trough , 178 (47.7%) were within the therapeutic range and 187 (50.1%) were subtherapeutic. The median posaconazole dose was significantly higher in patients under 2 (17.4 [IQR 12.6–23.7] mg/kg/day vs. 13.4 [IQR 12.0–18.4] mg/kg/day, P < 0.001). Nausea/vomiting (odds ratio [OR] 4.89; 95% confidence interval 2.09–11.44; P = 0.0003) and concomitant proton pump inhibitor use (OR 3.03; 95% confidence interval 1.15–7.95; P = 0.0248) were significantly associated with subtherapeutic C trough . Proven breakthrough invasive fungal infections occurred in 3 (4.2%) patients, with no statistically significant difference in subtherapeutic C trough values compared with the rest of the cohort ( P = 0.128). Toxicity was not related to supratherapeutic C trough . Conclusions: Our study highlights the importance of TDM in pediatric patients receiving posaconazole suspension, particularly those with risk factors associated with subtherapeutic C trough . Although further studies are needed to define the optimal dosage in children under 2, our findings suggest that these patients should receive at least 15 mg/kg/day.